ES2096936T3 - Agentes antianginales de piridopirimidinona. - Google Patents

Agentes antianginales de piridopirimidinona.

Info

Publication number
ES2096936T3
ES2096936T3 ES93917761T ES93917761T ES2096936T3 ES 2096936 T3 ES2096936 T3 ES 2096936T3 ES 93917761 T ES93917761 T ES 93917761T ES 93917761 T ES93917761 T ES 93917761T ES 2096936 T3 ES2096936 T3 ES 2096936T3
Authority
ES
Spain
Prior art keywords
alkyl
piridyl
co2r9
onyl
piridopirimidinona
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917761T
Other languages
English (en)
Inventor
Andrew Simon Bell
Nicholas Kenneth Terrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Research and Development Co NV SA
Original Assignee
Pfizer Research and Development Co NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research and Development Co NV SA filed Critical Pfizer Research and Development Co NV SA
Application granted granted Critical
Publication of ES2096936T3 publication Critical patent/ES2096936T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Liquid Crystal Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

COMPUESTOS DE FORMULA (I) Y SUS SALES ACEPTABLES FARMACEUTICAMENTE EN DONDE R1 ES H, ALQUILO C1 - C4, CN O CONR4R5; R2 ES ALQUILO C2 C4; R3 ES SO2NR6R7, NO2, NH2, NHCOR8, NHSO2R8 O N(SO2 R8)2; R4 Y R5 SON CADA UNO INDEPENDIENTEMENTE SELECCIONADOS ENTRE H Y ALQUILO C1 - C4; R6 Y R7 ESTAN SELECCIONADOS CADA UNO INDEPENDIENTEMENTE ENTRE H Y ALQUILO C1 - C4 OPCIONALMENTE SUSTITUIDO CON CO2R9, OH, PIRIDILO, ONILO - 3 - ISOXAZOLIN 5 O ONILO - 2 - IMIDAZOLIDIN - 1; O JUNTO CON EL ATOMO DE NITROGENO AL QUE ESTAN UNIDOS FORMAN UN PIRROLIDINO, PIPERIDINO, MORFOLINO, PIRAZOLIN - 1 O UN GRUPO PIPERACINILO - 1 (NR10) - 4 EN DONDE CUALQUIERA DE DICHOS GRUPOS PUEDEN ESTAR OPCIONALMENTE SUSTITUIDOS CON UNO O DOS SUSTITUYENTES SELECCIONADOS ENTRE ALQUILO C1 - C4, CO2R9, NH2 Y OH; R8 ES ALQUILO C1 - C4 O PIRIDILO; R9 ES H O ALQUILO C1 - C4 Y R10 ES H, ALQUILO C1 - C4 O (HIDROXI) ALQUILO C2 - C3; SON INHIBIDORES SELECTIVOS DE PDE GMPC UTILES EN EL TRATAMIENTO DE, "INTER ALIA", ENFERMEDADES CARDIOVASCULARES TALES COMO LA ANGINA, HIPERTENSION, FALLO CARDIACO Y ARTEROESCLEROSIS.
ES93917761T 1992-08-28 1993-08-04 Agentes antianginales de piridopirimidinona. Expired - Lifetime ES2096936T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929218322A GB9218322D0 (en) 1992-08-28 1992-08-28 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2096936T3 true ES2096936T3 (es) 1997-03-16

Family

ID=10721102

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917761T Expired - Lifetime ES2096936T3 (es) 1992-08-28 1993-08-04 Agentes antianginales de piridopirimidinona.

Country Status (12)

Country Link
US (1) US5591742A (es)
EP (1) EP0656898B1 (es)
JP (1) JP2660103B2 (es)
AT (1) ATE148118T1 (es)
CA (1) CA2138298C (es)
DE (1) DE69307712T2 (es)
DK (1) DK0656898T3 (es)
ES (1) ES2096936T3 (es)
FI (1) FI112484B (es)
GB (1) GB9218322D0 (es)
GR (1) GR3022852T3 (es)
WO (1) WO1994005661A1 (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298518A (en) * 1989-09-29 1994-03-29 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US5696159A (en) * 1994-08-03 1997-12-09 Cell Pathways, Inc. Lactone compounds for treating patients with precancerous lesions
US5776962A (en) * 1994-08-03 1998-07-07 Cell Pathways, Inc. Lactone compounds for treating patient with precancerous lesions
GB9423911D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6060477A (en) * 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6046206A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US6046216A (en) * 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US5874440A (en) * 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
BR9709230A (pt) * 1996-05-10 1999-08-10 Icos Corp Composto
US6723719B1 (en) 1997-04-25 2004-04-20 Pfizer Inc Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3′,5′—monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
CA2395558C (en) * 1997-11-12 2007-07-17 Bayer Aktiengesellschaft Intermediates for 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
US5852035A (en) * 1997-12-12 1998-12-22 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to substituted N- arylmethyl and heterocyclmethyl-1H-pyrazolo (3,4-B) quinolin-4-amines
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US5942520A (en) * 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
US5990117A (en) * 1998-04-15 1999-11-23 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
RS50011B (sr) * 1998-04-20 2008-09-29 Pfizer Inc., Derivati piridin-3-karboksilne kiseline i njihova upotreba kao intermedijera
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19827640A1 (de) 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
US6180629B1 (en) 1998-08-14 2001-01-30 Cell Pathways, Inc. [4,5]-Fused-1,3-disubstituted-1,2-diazine-6-one derivatives with nitrogen containing substitutents in position one for the treatment of neoplasia
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6124303A (en) * 1998-09-11 2000-09-26 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 9-substituted 2-(2-N-aloxyphenyl) purin-6-ones
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6225315B1 (en) 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
HK1049834A1 (zh) 1999-10-11 2003-05-30 辉瑞大药厂 用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
MXPA02006240A (es) * 1999-12-24 2003-01-28 Bayer Ag Nuevas imidazo[1,3,5,) triazinonas y su uso.
US6774128B2 (en) * 2000-04-19 2004-08-10 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
WO2001087888A1 (en) * 2000-05-17 2001-11-22 Sk Chemicals Co., Ltd. Pyrazolopyrimidinone derivatives, process for their preparation and their use
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US20040102324A1 (en) 2002-02-28 2004-05-27 Annis Gary David Heterocyclic diamide invertebrate pest control agents
ES2364550T3 (es) * 2001-03-05 2011-09-06 E. I. Du Pont De Nemours And Company Agentes de control de plagas de invertebrados de diamidas heterocíclicas.
WO2002089808A1 (de) * 2001-05-09 2002-11-14 Bayer Healthcare Ag Neue verwendung von 2-phenyl-substituierten imidazotriazinonen
DE60235198D1 (de) 2001-12-20 2010-03-11 Merck Serono Sa Coinsins Pyrrolidin-derivatie als prostaglandin-modulatoren
GB0202282D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Treatment of male sexual dysfunction
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
KR100490970B1 (ko) * 2002-03-22 2005-05-24 씨제이 주식회사 신규 피리도[2,3-ｄ]피리미딘 카르보알데히드 옥심계ＰＤＥ Ⅳ 효소 저해 화합물 및 이의 제조방법
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
AU2003303041B2 (en) 2002-12-13 2008-07-24 Warner-Lambert Company Llc Alpha-2-delta ligand to treat lower urinary tract symptoms
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
JP2007501866A (ja) * 2003-06-13 2007-02-01 マイクロバイア インコーポレイテッド 胃腸疾患の治療のための方法および組成物
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
BRPI0506994A (pt) 2004-01-22 2007-07-03 Pfizer derivados de triazol que inibem a atividade antagonista da vasopressina
EP1563741A1 (en) * 2004-02-12 2005-08-17 Campina Nederland Holding B.V. Skimmed milk product for consumption and method for its preparation
CA2562251C (en) 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
EP1863795B1 (en) 2005-03-21 2008-10-29 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
CA2608018C (en) 2005-05-12 2010-07-13 Pfizer Inc. Anhydrous crystalline forms of n-[1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl]methanesulfonamide
WO2007020521A1 (en) * 2005-08-16 2007-02-22 Pharmacia & Upjohn Company Llc Pyridoyrazinones as pde-5 inhibitors
JP2009509984A (ja) * 2005-09-29 2009-03-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 泌尿器系障害の処置用のｐｄｅ阻害剤およびそれらの組合せ
WO2008151734A1 (en) * 2007-06-13 2008-12-18 Bayer Schering Pharma Aktiengesellschaft Pde inhibitors for the treatment of hearing impairment
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
WO2013115884A2 (en) 2011-11-15 2013-08-08 Trustees Of Boston University Pyridopyrimidinone inhibitors of viruses
MX2016014384A (es) 2014-06-23 2017-01-20 Celgene Corp Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.
US11590209B2 (en) 2020-01-21 2023-02-28 Palatin Technologies, Inc. Use of bremelanotide in patients with controlled hypertension

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
JPS5393520A (en) * 1977-01-24 1978-08-16 Shin Meiwa Ind Co Ltd Canopy device for rear body of vehicle
SE406624B (sv) * 1977-07-12 1979-02-19 Stal Laval Turbin Ab Turbomaskin
JPS5670998A (en) * 1979-11-15 1981-06-13 Toppan Printing Co Ltd Laser carving method and mask board used for said method
ES2058527T3 (es) * 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
JPH0216563U (es) * 1988-07-19 1990-02-02
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents

Also Published As

Publication number Publication date
GR3022852T3 (en) 1997-06-30
JPH07506838A (ja) 1995-07-27
EP0656898A1 (en) 1995-06-14
DK0656898T3 (da) 1997-08-18
JP2660103B2 (ja) 1997-10-08
GB9218322D0 (en) 1992-10-14
WO1994005661A1 (en) 1994-03-17
ATE148118T1 (de) 1997-02-15
FI950889A7 (fi) 1995-02-27
DE69307712D1 (de) 1997-03-06
US5591742A (en) 1997-01-07
FI950889A0 (fi) 1995-02-27
EP0656898B1 (en) 1997-01-22
FI112484B (fi) 2003-12-15
DE69307712T2 (de) 1997-05-15
CA2138298C (en) 1998-04-14
CA2138298A1 (en) 1994-03-17

Similar Documents

Publication Publication Date Title
ES2096936T3 (es) Agentes antianginales de piridopirimidinona.
ES2092316T3 (es) Agentes antianginosos de purinona.
ES2114952T3 (es) Agentes antianginales derivados de quinazolinona.
CO4650042A1 (es) Derivados de 6-fenilpiridil-2-amina
MX9305930A (es) Derivados de piperidina, su preparacion y su aplicacion en terapeutica.
CA2044748A1 (en) Pyrazolopyrimidinone antianginal agents
DE69618231D1 (de) TETRAHYDROIMIDAZOPYRIDOINDOLDIONE ALS cGMP SPEZIFISCHE PDE HEMMER
ES2053609T3 (es) Derivados de urea inhibidores de lipoxigenasa.
FI944217L (fi) Substituoidut pipekoliinihappojohdannaiset HIV-proteaasin estäjinä
DE69512036D1 (de) Analoge von benzamid, zur verwendung als parp(adp-ribosyltransferase, adprt) dns-reparaturenzyminhibitoren
DE69315662D1 (de) Aminderivate als Korrosionsinhibitoren
UY24625A1 (es) Derivados de la 4-hidroxi-piperidina
ES2058265T3 (es) Piperidinas antagonistas de opiaceos.
AR026352A1 (es) Derivados de imidazopiridina como inhibidores de la fosfodiesterasa vii.
BR0004535A (pt) Compostos, e, uso dos mesmos.
CO4810374A1 (es) Nueva utilizacion de compuestos para actividad anti- pruritica
DE69619259D1 (de) Amidin- und isothioharnstoffderivate als inhibitoren der stickstoffoxid-synthase
CO5011117A1 (es) 1,2,3,4,5,6-hexahidro-2,6-metano-3-benzazocin-10-oles sustituidos y procedimiento para su preparacion .
UA41350C2 (uk) Похідна морфоліну або її фармацевтично прийнятна сіль та фармацевтична композиція на її основі
AR021970A1 (es) Inhibidores de proteasas
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos
CO4940439A1 (es) COMPUESTOS 4-AMINO-6,7-DISUSTITUIDOS-PIRIDO-[2,3-d] PIRIMI- DINA
ES2065992T3 (es) Uso de derivados de imidazopirazol como analgesicos y agentes anti-inflamatorios.
NO932002L (no) Nye tiosemikarbazonsyreestere
ES8605265A1 (es) Procedimiento para la obtencion de la 8-(4-(4-(2-pirimidi- nil)-1-piperazinil)butil)-8-azaspiro(4,5)decano-7,9-diona y su clorhidrato

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 656898

Country of ref document: ES